Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel

Results for "

KCNQ channel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (2) Histamine Receptor (1) Potassium Channel (32) Reference Standards (5) TRP Channel (2)
By Research Areas:	Cardiovascular Disease (7) Inflammation/Immunology (4) Neurological Disease (25)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12343

ML277 1 Publications Verification CID-53347902	Potassium Channel	Cardiovascular Disease
ML277 (CID-53347902) is a potent and selective activator of K(v)7.1 (KCNQ1) potassium channel activator (EC₅₀=270 nM), rescues function of pathophysiologically important mutant channel complexes in human induced pluripotent stem cell-derived cardiomyocytes .

HY-108577

XE991 dihydrochloride 3 Publications Verification	Potassium Channel	Neurological Disease
XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC₅₀s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .

HY-122114

ICA-27243 1 Publications Verification	Potassium Channel	Neurological Disease
ICA-27243 is a selective, potent and orally active **KCNQ2/Q3 potassium channel opener with an EC₅₀** of 0.38 μM. ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 has antiepileptic and anticonvulsant effects .

HY-108577A

XE991 3 Publications Verification	Potassium Channel	Neurological Disease
XE 991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC₅₀s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .

HY-18063

ML252	Potassium Channel Cytochrome P450	Neurological Disease
ML252 is a selective inhibitor of KCNQ2 (Kv7.2) channel with an IC₅₀s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 also inhibits Cytochrome P450 with IC₅₀s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 shows highly brain penetrant .

HY-101396

ICA-069673 3 Publications Verification	Potassium Channel	Neurological Disease
ICA-069673 is a *KCNQ2/Q3* potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC₅₀s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells .

HY-W020468

Linopirdine 2 Publications Verification DuP 996	Potassium Channel TRP Channel	Neurological Disease
Linopirdine (DuP 996) is an orally active, selective M-type K ⁺ current (IM; Kv7; KCNQ Channels) inhibitor with an IC₅₀ of 2.4 μM. Linopirdine is a TRPV1 agonist. Linopirdine, a putative cognition enhancing agent, increases acetylcholine release in rat brain tissue .

HY-108587

ICA 110381	Potassium Channel	Neurological Disease
ICA 110381 is an orally active Kv7.2/Kv7.3 (KCNQ2/3) potassium channel activator with anticonvulsive properties. ICA 110381 is a *KCNQ2*/Q3 activator (EC₅₀=0.38 μM) as well as *KCNQ1* antagonist (IC₅₀=15 μM) .

HY-157485

Ebio1	Potassium Channel	Others
Ebio1 is a selective voltage-gated potassium channel *KCNQ2* activator. Ebio1 activates *KCNQ2* by generating an extended channel gate with greater conductance at a saturation voltage (+50 mV) .

HY-108591

L-364,373 R-L3	Potassium Channel	Cardiovascular Disease
L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .

HY-123264

RL648_81	Potassium Channel	Neurological Disease
RL648_81 is a specific KQT-like subfamily 2/3 (KCNQ2/3) activator with an EC₅₀ of 190 nM. RL648_81 robustly shifts the V1/2 of KCNQ2/3 channels towards hyperpolarized potentials.RL648_81 does not shift the V1/2 of either KCNQ4 or KCNQ5.RL648_81 has?the?potential?for?neurologic disorders associated with neuronal hyperexcitability research .

HY-108592

UCL 2077	Potassium Channel	Cardiovascular Disease Neurological Disease
UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca ²⁺ currents. UCL 2077 blocks *KCNQ1- and KCNQ2*-containing K ⁺ channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias .

HY-P5925A

Ssm spooky toxin TFA SsTx Toxin TFA	Potassium Channel	Neurological Disease Inflammation/Immunology
Ssm Spooky Toxin TFA is found in Scolopendra mutilans that potently inhibits **KCNQ (voltage-gated potassium channel family 7) channels, with IC₅₀*s of 2.8 μM, 5.26 μM and 0.1-0.3 M for Kv7.4, Kv1.3, and Shal channel, respectivily. Ssm Spooky Toxin TFA inhibits cytokine generation by specifically acting on the KV1.3 channel* in T cells. Ssm Spooky Toxin TFA plays an essential role in the centipede’s circulatory system .

HY-121977

IKs124	Potassium Channel	Inflammation/Immunology
IKs124 is *KCNE2/KCNQ1* potassium channel blocker with the with an IC₅₀ of 8 nM. IKs124 can be used for study of peptic ulcers .

HY-115823

ztz240	Potassium Channel	Neurological Disease
ztz240 is a chemical modulator of voltage-gated potassium channel Kv7 (KCNQ) (KCNQ2 and 3: EC₅₀=6.1 μM; *KCNQ4: EC₅₀*=12.2 μM). ztz240 can be used in analgesia and anti-epileptic research .

HY-179065

VU0494372	Potassium Channel	Cardiovascular Disease
VU0494372 is an activator of potassium ion channel KCNQ1. VU0494372 can significantly enhance the cell surface expression and transport efficiency of KCNQ1. VU0494372 does not alter KCNQ1 mRNA levels and protein degradation rate, and has no significant cytotoxicity. VU0494372 can be used for research on cardiovascular conditions .

HY-122504

Linoleoyl glycine	Potassium Channel	Neurological Disease
Linoleoyl glycine is a modified polyunsaturated fatty acid. Linoleoyl glycine has activating effects on human KCNQ1/KCNE1 (hKCNQ1/hKCNE1) channels expressed in Xenopus oocytes .

HY-172140

Ebio3	Potassium Channel	Neurological Disease
Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC₅₀ of 1.2 nM. Ebio3 binds to the *KCNQ2* channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy .

HY-P5925

Ssm spooky toxin SsTx Toxin	Potassium Channel	Neurological Disease Inflammation/Immunology
Ssm Spooky Toxin is found in Scolopendra mutilans that potently inhibits **KCNQ (voltage-gated potassium channel family 7) channels, with IC₅₀*s of 2.8 μM, 5.26 μM and 0.1-0.3 M for Kv7.4, Kv1.3, and Shal channel, respectivily. Ssm Spooky Toxin inhibits cytokine generation by specifically acting on the KV1.3 channel* in T cells. Ssm Spooky Toxin plays an essential role in the centipede’s circulatory system .

HY-117174

L-735821	Potassium Channel	Cardiovascular Disease
L-735821 is a Potassium channel blocker and an antagonist of I_Ks. L-735821 inhibits the KCNQ1 channel activity with an EC₅₀ of 0.08 μM. L-735821 can increase I_Ks and I_Kr current-voltage relations in rabbit ventricular myocytes. L-735821 fully abolishes I_Ks in isolated human ventricular myocytes at 100 nmol/L. L-735821 can easily enter single myocytes .

HY-W020468R

Linopirdine (Standard) DuP 996 (Standard)	Reference Standards Potassium Channel TRP Channel	Neurological Disease
Linopirdine (DuP 996) is an orally active, selective M-type K+ current (IM; Kv7; KCNQ Channels) inhibitor with an IC50 of 2.4 μM. Linopirdine is a TRPV1 agonist. Linopirdine, a putative cognition enhancing agent, increases acetylcholine release in rat brain tissue .

HY-145992

KCNQ1 activator-1	Potassium Channel	Cardiovascular Disease Neurological Disease
KCNQ1 activator-1 (compound 5) is a potent activator of *KCNQ1* channel with an EC₅₀ of 1.69 μM. KCNQ1 activator-1 has the potential for the research of long QT syndrome (LQTS) .

HY-108577R

XE991 dihydrochloride (Standard)	Potassium Channel	Neurological Disease
XE991 dihydrochloride (Standard) is the analytical standard of XE991 dihydrochloride. This product is intended for research and analytical applications. XE991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .

HY-130070

QO-40	Potassium Channel	Neurological Disease
QO-40, a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative, is a *KCNQ2/KCNQ3* K ⁺ channels activator with an EC₅₀ of 6.94 μM. QO-40 stimulated Ca ²⁺-activated K ⁺ current (I_K(Ca)) with an EC₅₀ value of 2.3 μM in pituitary GH3 lactotrophs .

HY-18063A

ML252 hydrochloride	Potassium Channel Cytochrome P450	Neurological Disease
ML252 hydrochloride is a selective inhibitor of KCNQ2 (Kv7.2) channel with IC₅₀s of 69 nM, 2.92 μM, 0.12 μM and 0.20 μM for KCNQ2, KCNQ1 (Kv7.1), KCNQ2/Q3 and KCNQ4, respectively. ML252 hydrochloride also inhibits Cytochrome P450 with IC₅₀s of 6.1 nM (CYP1A2), 18.9 nM (CYP2C9), 3.9 nM (CYP3A4), 19.9 nM (CYP2D6), respectively. ML252 hydrochloride shows highly brain penetrant .

HY-168214

Kv7.2/Kv7.3 agonist 1	Potassium Channel	Neurological Disease
Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC₅₀ of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED₅₀ of 12.02 and 9.63 mg/kg .

HY-118807A

Mepyramine hydrochloride Pyrilamine hydrochloride	Histamine Receptor Potassium Channel	Neurological Disease Inflammation/Immunology
Mepyramine hydrochloride (Pyrilamine hydrochloride) is a selective histamine H1 receptor antagonist and *KCNQ* channel inhibitor, with an IC₅₀ of 12.5 μM against *KCNQ2/Q3*. Mepyramine hydrochloride shows no activity against allergic asthma in mice when used alone, but modulates the effect of JNJ 7777120 (HY-13508) on allergic asthma in mice; it inhibits the development of morphine physical dependence and increases histamine levels in mouse brains. Mepyramine hydrochloride can be used in studies related to seizures, convulsions, allergic asthma and morphine physical dependence .

HY-181128

QO-83	Potassium Channel	Neurological Disease
QO-83, Retigabine analogue, is a *voltage-gated potassium channel* KCNQ2 (Kv7.2) activator with an EC₅₀** of 0.56 μM. QO-83 binds to a single hydrophobic pocket of KCNQ2-CaM complex in closed conformation. QO-83 induces a negative shift in the voltage-dependent activation curve of KCNQ2 channels, increasing the channel's voltage sensitivity. QO-83 can be used for the research of epilepsies .

HY-108577AR

XE991 (Standard)	Potassium Channel Reference Standards	Neurological Disease
XE991 (Standard) is the analytical standard of XE991 (HY-108577A). This product is intended for research and analytical applications. XE 991, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC₅₀s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively .

HY-108592R

UCL 2077 (Standard)	Reference Standards Potassium Channel	Neurological Disease
UCL 2077 (Standard) is the analytical standard of UCL 2077 (HY-108592). This product is intended for research and analytical applications. UCL 2077 is a selective slow-afterhyperpolarization (sAHP) channel blocker (IC₅₀ = 500 nM in hippocampal neurons in culture), having minimal effects on Ca2+ channels, action potentials, input resistance and the medium after hyperpolarization . UCL 2077 is also a subtype-selective blocker of the epilepsy associated KCNQ channels .

HY-108591R

L-364,373 (Standard) R-L3 (Standard)	Reference Standards Potassium Channel	Cardiovascular Disease
L-364,373 (Standard) is the analytical standard of L-364,373 (HY-108591). This product is intended for research and analytical applications. L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .

HY-101396R

ICA-069673 (Standard)	Potassium Channel Reference Standards	Neurological Disease
ICA-069673 (Standard) is the analytical standard of ICA-069673 (HY-101396). This product is intended for research and analytical applications. ICA-069673 is a KCNQ2/Q3 potassium channel activator. ICA-069673 demonstrates greater selectivity for KV7.2/7.3 over KV7.3/KV7.5, with EC50s of 0.69 μM and 14.3 μM, respectively. ICA-069673 inhibits spontaneous phasic and nerve-evoked contractions in guinea pig detrusor smooth muscle (DSM). ICA-069673 also decreases the global intracellular Ca(2+) concentration in DSM cells .

Cat. No.	Product Name	Target	Research Area

HY-P5925A

Ssm spooky toxin TFA SsTx Toxin TFA	Potassium Channel	Neurological Disease Inflammation/Immunology
Ssm Spooky Toxin TFA is found in Scolopendra mutilans that potently inhibits **KCNQ (voltage-gated potassium channel family 7) channels, with IC₅₀*s of 2.8 μM, 5.26 μM and 0.1-0.3 M for Kv7.4, Kv1.3, and Shal channel, respectivily. Ssm Spooky Toxin TFA inhibits cytokine generation by specifically acting on the KV1.3 channel* in T cells. Ssm Spooky Toxin TFA plays an essential role in the centipede’s circulatory system .

HY-P5925

Ssm spooky toxin SsTx Toxin	Potassium Channel	Neurological Disease Inflammation/Immunology
Ssm Spooky Toxin is found in Scolopendra mutilans that potently inhibits **KCNQ (voltage-gated potassium channel family 7) channels, with IC₅₀*s of 2.8 μM, 5.26 μM and 0.1-0.3 M for Kv7.4, Kv1.3, and Shal channel, respectivily. Ssm Spooky Toxin inhibits cytokine generation by specifically acting on the KV1.3 channel* in T cells. Ssm Spooky Toxin plays an essential role in the centipede’s circulatory system .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703261

	KCNQ4 Protein, Human (HEK293) Potassium voltage-gated channel subfamily KQT member 4; KQT-like 4; Potassium channel subunit alpha KvLQT4; Voltage-gated potassium channel subunit Kv7.4; KCNQ4; Homo sapiens; Human; Ion channel; Potassium channel; Voltage-gated channel;	Human	HEK293
	KCNQ4 Protein, Human (HEK293) is the recombinant human-derived KCNQ4, expressed by HEK293 , with tag Free labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-172140

Ebio3		Alkynes
Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC₅₀ of 1.2 nM. Ebio3 binds to the *KCNQ2* channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: